Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis.

Olmedo Martín, Raúl Vicente

Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis. [electronic resource] - Revista espanola de enfermedades digestivas Sep 2017 - 659-662 p. digital

Publication Type: Case Reports; Journal Article

1130-0108

10.17235/reed.2017.5024/2017 doi


Adult
Antibodies, Monoclonal, Humanized--adverse effects
Cholangitis, Sclerosing--surgery
Colitis, Ulcerative--drug therapy
Female
Gastrointestinal Agents--adverse effects
Humans
Liver Transplantation
Treatment Outcome